Nalpropion Pharmaceuticals, Inc. Expands Agreement with iNova Pharmaceuticals for Exclusive Commercialization Rights for Contrave® (naltrexone HCl / bupropion HCl extended release) to include Select Markets in Southeast Asia, Africa and the Pacific
December 19, 2018 11:36 ET
|
Nalpropion
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Nalpropion Pharmaceuticals, Inc. (Nalpropion) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Limited (OTIL), and...